

Sustainability

2020 GOALS PROGRESS UPDATE



Transforming patients' lives
through science™

Sustainability

2020 GOALS PROGRESS UPDATE

CONTENTS


Priority Assessment Map	3
Sustainable Development Goals (SDGs)	4
Our Goals and Objectives	6
Our Pipeline	12
Patients	13
People	16
Business	18
Principles of Integrity	23

Priority Assessment Map

In 2014, we conducted a formal assessment to update our key sustainability issues, based on forward-looking views of global sustainability issues and stakeholder concerns.

We identified a broad set of issues, drawn from the input of senior executives and a wide range of external stakeholders.

- This range of stakeholders included:**
- Sustainable Investment Groups
 - Shareholders
 - Partners
 - Patient Advocacy Groups
 - Multilateral Organizations
 - Non-Governmental Organizations (NGOs)
 - Academia



Internal interviews of cross-functional and business unit leads were conducted to assess the most important issues to business success. Select external interviews were conducted with organizations representative of key issue areas (e.g., global health, access to medicines, product stewardship, climate, transparency) and types of organizations (e.g., NGOs, patient advocacy organizations, sustainable investors, academics) to determine relative priority of issues to external stakeholders.

The interviews focused on highlighting the top priorities, rising trends, risks and opportunities, and challenges to implementation.

The issues were then mapped (see graphic above) to highlight their relative priority to business success and stakeholders, based on input from the interviews. The results of the mapping were reviewed and refined with further input from our Sustainability Council and senior executive management. The higher priority issues were consolidated into a framework to inform sustainability strategy moving forward.

In 2019, we refreshed our priority issue assessment as a key first step in the development of our next-generation sustainability goals. The refreshed priority issues are mapped to three pillars reflecting our core strategic components of Patient Centricity, Ethical Business and Human Capital Management.

Sustainable Development Goals (SDGs)

A COMPREHENSIVE APPROACH TO SUSTAINABILITY GOALS

Bristol Myers Squibb has a transparent process in place to set, prioritize and measure the success of sustainability goals that are relevant to our business and ultimately have the potential to make a true impact on society. In 2010, Bristol Myers Squibb signed the UN Global Compact and submitted our annual Communication of Progress under the Advanced category.

In September 2015, all 193 Member States of the United Nations adopted “Agenda 2030,” a 15-year plan to end extreme poverty, fight inequality and injustice, and protect our planet. At the center of Agenda 2030 are the 17 Sustainable Development Goals (SDGs) that give a clear roadmap for the work required to achieve the agenda. The SDGs provide a universal and visionary framework for this global cooperation and action and bring all stakeholders together to proactively address and solve these challenges.

SUSTAINABLE DEVELOPMENT GOALS



The Bristol Myers Squibb mission, values and purpose fully align with the UN SDGs. Since 2016, we have reported progress toward seven targets within Goal 3, Good Health and Well-Being, through the efforts of Bristol Myers Squibb Company in collaboration with the BMS Foundation and the BMS Patient Assistance Foundation.

In 2018, we were a sponsor for the inaugural One Young World Lead2030 Challenge, supporting Goal 10, Reduced Inequalities, with a focus on equality within the LGBTQ community. Our commitment to this SDG and focus area is reflected in our continued sponsorship for the 2019 Challenge. In addition, we are members of the inaugural UN Young SDG Innovators Programme, supporting Goal 3, Good Health and Well-Being, focusing on Mental Health and Wellness.

Our longer-term vision and approach to business growth and planning have given us a clear understanding of how important it is to provide innovative solutions to global sustainability and to incorporate sustainability into our corporate culture and daily business operations. As we work on transforming our models and systems for the future, we remain committed to the continued evolution of environmentally sound and socially responsible growth.


SDG Alignment



PRIMARY GOALS

We leveraged the SDG Compass to best map our sustainability efforts across the enterprise and align our strategy to the realization of the SDGs. Through this exercise, we identified 10 SDGs, defined by our primary and secondary alignment and mapped to the efforts and impact to both our business and our patients.

Our Primary Goals correspond to efforts that support our core value chain. These efforts are directly involved in the identification, development and distribution of life-saving medicines to our patients.



SECONDARY GOALS

Secondary Goals correspond to programs driving Diversity and Inclusion and Environmental Responsibility within our sites and in the communities in which we operate.

Our Goals & Objectives

The company's approach to sustainability is comprehensive and global and encompasses the products we make and how we make them, our facilities, our employees and our communities.


Bristol Myers Squibb has been setting sustainability objectives and reporting on results since the 1990s, when we began reporting on environmental objectives. In 2000, we launched our Sustainability 2010 Goals and broadened our focus to include social issues. In 2009, we introduced our Sustainability 2015 Goals, which addressed a fresh set of issues and targets, while continuing to focus on a number of key areas.

To develop our Sustainability 2020 Goals, we worked across the organization to facilitate priority assessments by interviewing senior leaders and benchmarking against other companies—inside and outside of the industry—to build alignment and ownership of the goals.

The Bristol Myers Squibb Sustainability 2020 Goals align with the company's strategy and with programs underway across the organization focused on innovation in support of research and development, patient access, our employees, our supply chain and the environment.

THE RESULT

A set of goals designed to further strengthen the company's business foundation, enabling an even stronger platform for future growth through opportunities to meet patient needs and stakeholder expectations



2020 Goals Status

Goal 1

Accelerate innovation and develop transformative medicines



ONGOING FOCUS AREAS

Focus therapeutic efforts on transformative medicines in areas of high unmet medical need that leverage our R&D expertise.

Accelerate product development and review while ensuring data integrity and adherence to regulatory standards.

Conduct research and development programs with transparency, through public disclosure of all ongoing clinical trials and trial results for approved products.

Recruit clinical trial patients representing the patient population.

Seek patient, healthcare provider (HCP) and/or caregiver feedback through advocacy alliances or other means.

2020 TARGETS

All R&D processes will be designed to optimize development timelines to generate the desired data package and expedite regulatory review.

Continue to ensure all trial results are published in accordance with FDAAA 801 requirements. Launch Study Connect 3.0 in Q2 2018, which will serve as an awareness platform for patients and their caregivers, enabling understanding of industry-wide clinical trial programs and support.

Improve the opportunity of clinical trial participation to reflect a real-world population through ensuring inclusion of clinical trial sites to serve diverse patient populations.

Identify and solicit input into the universal patient language incorporated into patient and caregiver materials. Develop materials that are culturally relevant. Both of these areas will enhance patient and caregiver awareness of clinical trials and understanding of participation within clinical trials.

STATUS AS OF DEC 2018

R&D pipeline continued to focus on key therapeutic areas for patients with 41 compounds in development.

Implemented a new enterprise product development and commercialization governance to ensure high-quality decisions at key stage gates for the New BMS.

Bristol Myers Squibb ranked #1 in Clinical Trial Transparency by Bioethics International's 2015 Good Pharma Scorecard, awarded in May 2018.

Launched Study Connect 3.0, an industry-leading clinical trial awareness platform for patients and their caregivers May 2018; rollout to additional countries ongoing through 2019.

Clinical trial site selection now includes a focus on identifying and partnering with sites that serve diverse populations, continuing our drive toward trials that reflect a real-world population.

BMS achievements to effectively connect with patients, caregivers and HCPs across the globe include publishing Study Connect and trial-related materials in English and local languages in more than 15 countries and the creation of formal and informal engagement efforts to embed feedback from across the healthcare continuum.

2020 Goals Status

Goal 2

Enhance patient access to medicines



ONGOING FOCUS AREAS

Offer creative tiered pricing, voluntary licensing, reimbursement support and patient assistance programs to optimize access while protecting innovation.

Advocate for sustainable healthcare policies and infrastructure, leveraging advocacy/payer input and utilizing partnerships as appropriate.

Improve access to care and supportive services for vulnerable patients through partnerships and demonstration projects.

2020 TARGETS

All marketed products will have plans to enable greater access to the value of our medicines globally, as appropriate, using tiered pricing, voluntary licensing, reimbursement support and patient assistance programs.

All access plans will include stakeholder engagement and leverage data that help relevant healthcare resource allocation.

80% of BMS Foundation partnerships will result in health equity improvement for target populations.

STATUS AS OF DEC 2018

We have plans and/or activities in place to enable greater access for 100% of our marketed products. This includes the use of a direct import model, covering markets (countries) where the respective products are not registered.

Access plans and stakeholder engagement are managed at the country/affiliate level for all markets within our footprint.

We are exceeding the target of 80% of BMS Foundation partnerships resulting in health equity improvement for target populations.

2020 Goals Status

Goal 3

Empower our people with an energizing work environment and safety culture



ONGOING FOCUS AREAS

Empower our people with an energizing work environment and safety culture.

Engage our people in a culture of inclusion and diversity that drives business performance throughout the value chain and leverages their insights to better meet patient needs. Drive year-on-year improvement of the employee culture survey Inclusion Index.

Be an employer of choice by investing in our people through innovative professional development, skill building and personal leadership opportunities.

2020 TARGETS

Improve safe behaviors through leadership initiatives and communications, measured through new safety culture survey.

Have a globally diversified and more gender-balanced workforce.

Double the number of strategic partnerships and networks with academia and professional organizations/associations to source diverse talent for Bristol Myers Squibb.

Recognized as an employer of choice through more global external surveys and recognition.

STATUS AS OF DEC 2018

Five extensive, enterprise-wide safety initiatives have been launched; success of implementation into the company culture measured not only by an annual safety culture survey but also by enterprise-wide reporting of monthly metrics and an annual safety award.

Our ability to maintain gender parity across our global workforce has been supported through increased executive representation of women by nearly 5% in the last four years to 39%. In the United States, our representation of underrepresented ethnic groups has increased by nearly 4% to 34%.

Seventeen strategic partnerships to source diverse talent have been established since 2016. Prior to 2016, we did not have any such partnerships.

In the last five years, our number of corporate awards received has increased by 60%, totaling 15 in 2018, with greater recognition given for our work in diversity and inclusion.

2020 Goals Status

Goal 4

Drive supply chain leadership on quality and integrity



ONGOING FOCUS AREAS

Ensure reliable supply of materials through engagement with suppliers on quality and sustainability.

Engage critical suppliers to manage climate change impact and increase public disclosure.

Review critical third-party manufacturing supplier sites in high-risk countries for conformance with Bristol Myers Squibb environmental, health and safety (EHS), labor and integrity standards for suppliers.

2020 TARGETS

All critical manufacturing suppliers assessed for risk and risk mitigation performance, with results incorporated in sourcing decisions.

Engage with more than five critical suppliers in sustainability initiatives.

More than 75% of Tier 1 transportation miles of products evaluated for carbon reduction.

More than 75% of critical suppliers in high-risk countries reviewed for EHS, labor and integrity.

STATUS AS OF DEC 2018

All critical manufacturing suppliers are assessed through the BMS Procurement Risk Assessment and Mitigation tool. In addition, these suppliers are evaluated through third party-managed supply chain surveys (CDP and EcoDesk).

We are exceeding the target of more than five supplier engagements. In this report, we describe six of our active sustainability efforts with key suppliers.

We are exceeding the target of more than 75%. Through collaboration with our main service providers in primary distribution (KN, DHL and DSV), we are actively capturing sustainability metrics for more than 75% of our Tier 1 transportation miles.

All deliverables are complete, and we will exceed our goal, as we are on track to perform assessments at 100% of critical suppliers in high-risk countries by end of 2020.

2020 Goals Status

Goal 5

Innovate to support a green, healthy planet



ONGOING FOCUS AREAS

Improve our environmental footprint.

Integrate green design and reduce waste throughout our product portfolio.

2020 TARGETS

5% (absolute) or greater reduction of water and greenhouse gas (GHG) emissions from 2015 baseline.

Evaluate water/wastewater risk at key Bristol Myers Squibb facilities and develop response plans to address priority risk items.

More than 90% of new products in R&D portfolio assessed for improved environmental impact.

More than 90% of packaging of prioritized products assessed for improved environmental impact.

STATUS AS OF DEC 2018

Reduced operation-generated GHG emissions 10.44% and water use 4.3%.

Completed 10/13 site visits for evaluation and action plans related to enterprise water risks; on track to complete all site visits by Q4 2019.


100% of new products in R&D portfolio assessed for improved environmental impact.

100% of prioritized product packaging assessed for improved environmental impact.

Our Pipeline

Goal 1 | Accelerate innovation and develop transformative medicines

We are transforming the way certain cancers are treated and focusing our research efforts on areas of high unmet need in cardiovascular disease, immunoscience and fibrosis. Our goal is to leave an enduring positive impact on society by making a meaningful difference in the lives of even more patients.



* Based on the 2018 pipeline



We are constantly anticipating what's coming next, navigating and discovering new technologies, enabling our understanding of new ways to use them, and applying them to advance drug discovery, development and delivery to patients as quickly as possible.

Patients

Goal 2 | Enhance patient access to medicines



PATIENT ASSISTANCE FOUNDATION US SUPPORT

2016	2017	2018
Nearly 46,885 patients RECEIVED SUPPORT in the amount of \$732.8 million	Nearly 63,864 patients RECEIVED SUPPORT in the amount of \$862.2 million	Nearly 75,707 patients RECEIVED SUPPORT in the amount of \$1.04 billion

The Bristol Myers Squibb Patient Assistance Foundation assists patients in the United States who need temporary help paying for medication.



The Bristol Myers Squibb Foundation **promotes health equity and seeks to improve the health outcomes** of populations disproportionately affected by serious diseases by **strengthening healthcare worker capacity, integrating medical care and community-based supportive services and mobilizing communities in the fight against disease.**

ACHIEVEMENTS THROUGH CURRENT GRANTS AND PARTNERSHIPS

 23,303 HEALTHCARE WORKERS TRAINED	 703,039 PEOPLE IN TARGET COMMUNITIES REACHED	 \$149 MILLION COMMITTED TO CURRENT GRANTEE PROJECTS	 65 ACTIVE PROJECTS 11 COUNTRIES, 48 STATES
--	---	--	---

Patients

Goal 2 | Enhance patient access to medicines

Global HOPE (Hematology-Oncology Pediatric Excellence) is a \$50 million pediatric hematology-oncology initiative to address diagnosis, treatment and care in southern and East Africa. The Bristol Myers Squibb Foundation is collaborating with longtime partners Texas Children's Cancer and Hematology Centers, Baylor College of Medicine International Pediatric AIDS Initiative, and the governments of Botswana, Uganda and Malawi to create a treatment network and training hubs.



Since 1999, the Bristol Myers Squibb Foundation's **SECURE THE FUTURE** initiative has worked with partners in sub-Saharan Africa to provide care and support for communities affected by HIV and co-morbid conditions.

In 2003, **SECURE THE FUTURE** program and partners opened the first pediatric HIV treatment center and national training program on the continent of Africa, located in Botswana. Now in five countries, our pediatric HIV treatment network has helped train 52,000 healthcare professionals and provide care for more than 375,000 children and family members.



SECURE THE FUTURE'S focus has evolved to now help address the African continent's next major health challenge: cancer. As many people with HIV are not living longer, many are not dying of the virus but rather non-communicable diseases such as hypertension and cancer. In 2016, **SECURE THE FUTURE** began to create partnerships based on years of experience in HIV to address lung, cervical, breast, multiple myeloma and pediatric cancers and blood disorders.

In the United States, 80% of children with cancer survive. Shockingly, in sub-Saharan Africa, 90% of pediatric cancer and hematology patients die, due to a significant lack of a trained healthcare workforce and treatment capacity.



In 2017, the Bristol Myers Squibb Foundation leveraged 18 years of experience in HIV/AIDS to create **Global HOPE**, a pediatric hematology-oncology initiative in partnership with Texas Children's Hospital and Baylor International Pediatric AIDS Initiative.

With more than 100,000 new cases of pediatric cancer in Africa each year, it is critical to increase the number of trained healthcare professionals in this region.



Global HOPE will build long-term capacity to treat pediatric blood disorders and cancers with African, US and European healthcare providers providing on-site training to local medical professionals and medical students.



Global HOPE aims to train an estimated 5,000 healthcare providers from Botswana, Malawi, Uganda and other African countries in the first five years of the program and has already treated thousands of children.

Patients

Goal 2 | Enhance patient access to medicines

Access Accelerated is a partnership of more than 20 biopharmaceutical companies committed to addressing the increasing challenges of non-communicable diseases (NCDs) in low- and middle-income countries. Access Accelerated is committed to working toward a future where no one dies prematurely from NCDs and all people living with risk have access to appropriate treatment, prevention and care.

By collaborating with partners, Access Accelerated is working to achieve the UN SDGs and the target to reduce premature deaths from NCDs by one-third by 2030.

Bristol Myers Squibb has partnered with The Max Foundation for many years on treatment access and formalized the collaboration in 2016 to make Sprycel® available to patients in low-income and lower-middle-income countries.

“The missions of Bristol Myers Squibb and The Max Foundation are very much aligned,” says Cathy Trzaskawka, head of Global Advocacy at Bristol Myers Squibb. “Together, we are working in hopes to change the lives of patients with CML.”

Sprycel has become a game changer for patients with CML in countries in which patients lack access to targeted therapies because of cost and availability. “The only thing worse than hearing that your loved one has cancer is to hear that there is a treatment, but because of where you live, you can’t have it,” says Pat Garcia-Gonzalez, Max’s stepmother and CEO of The Max Foundation. “By working together with partners such as Bristol Myers Squibb, we are able to help change that.”

 The Max Foundation
has partnered with

2,791 physicians in 117 countries

186 patients in 17 countries
have received Bristol Myers Squibb medicines
through The Max Foundation

Donation of product is valued at
\$12.2 million

ACCESS ACCELERATED



People

Bristol Myers Squibb's PBRGs are an integral part of our commitment to developing a global, ethnically diverse and gender-balanced workforce, and they play an essential role in our business strategy.

Last year, we completely transformed our PBRGs from primarily social networking groups into businesses, each headed by a full-time lead who will create organizational and business structures to support our strategy and help us better meet the needs of patients worldwide.



Goal 3 | Empower our people with an energizing work environment and safety culture

Collaboration across all eight People and Business Resource Groups (PBRGs) in STEM (Science, Technology, Engineering and Math). **In 2018, 120 volunteers have supported our STEM efforts, projected to impact 400 students.**

Partnered with our R&D organization in China to launch a global buddy system designed to mentor colleagues new to clinical development in China, resulting in the accelerated launch of Opdivo®.

Introduced a set of transgender guidelines in the United States and Canada to ensure a respectful and inclusive workplace environment for employees in the process of gender transition. Approval of the guidelines for our Canada sites is planned for 2019.

Partnered with the Oncology Academic Research group for the Health Equities Forum, which brought together 23 external leaders in the field of Health Equities from major cancer centers across the United States with 15 Bristol Myers Squibb leaders to discuss barriers to diversity in clinical trials and identify potential solutions.

Collaborated with HISPA and the Center for Hispanic Policy, Research and Development in support of the New Jersey Governor's Hispanic Fellows Program. **During these four years, more than 100 fellows who are pursuing various college degrees have been positively impacted.**

Supported a US policy change in support of women and families, resulting in a US Paid Family Care Leave Policy. This new policy doubled paid parental leave for birth mothers from 6–8 weeks to 14–16 weeks, ensured other parents now have 8 weeks paid parental leave, including adoptive and foster parents, and provides for flexible work arrangements where appropriate.


Collaborated with CancerCare to provide resources on physical and mental health to young folks with cancer.

People

Goal 3 | Empower our people with an energizing work environment and safety culture

2018 CUMULATIVE

As part of our ongoing investment in our people, Bristol Myers Squibb has implemented a global catalog and calendar of course and webinar offerings enabling each individual to take greater ownership of their development. In addition, we've incorporated five innovative platforms to drive development, skill building and professional leadership opportunities across the enterprise.



SAFETY

Bristol Myers Squibb is committed to protecting the environment and the health and safety of its employees, contractors, customers and the public by conducting business in a safe and environmentally sustainable manner. Safety is central to what we do and how we do it, in every part of our company and in every part of the world. Regardless of position, regardless of place within our organization, each person has responsibility for their safety and for those around them.

Our sustainability goals support efforts to develop and deliver a global strategy to enhance safety performance and drive shared ownership of safety programs focused on compliance, training and continuous improvement.

Launched a company-wide safety culture survey

Introduced the Life Saving Rules (LSRs) and Serious Injury & Fatality (SIF) Prevention Management Program

Launched “Make Safety Personal” campaign

Introduced new BMS Safety Award

Created Management Engagement Measures for Safety

“Think Smart/Work Safe” campaigns

Business

Goal 4 | Drive supply chain leadership on quality and integrity

PACKAGING

Improving the sustainability profile of our products and packaging has long been an integral part of our environmental goals. Efforts to reduce waste throughout our product portfolio involve environmental life cycle analyses of product packaging. This includes the implementation of software that assists in identifying the environmental impact of packing material. We are committed to enhancing our continuous improvement process and meeting or exceeding applicable EHS standards throughout the product life cycle.

OPDIVO® and ORENCIA® packaging optimization efforts resulted in **50% reductions** in transportation-related GHG emissions as well as **\$3.0 million** in transportation costs annually

SHIPPING

Bristol Myers Squibb's logistics operation is continually looking for opportunities to conserve energy and reduce carbon emissions, and sustainability is ingrained in our vendor management process. We look for and encourage our vendors to make changes that will lead to more efficient ways of transporting our products, and during our selection process, we carefully review the vendor's sustainability score.



Achieved **60%** of our oncology and immunology volumes shipped via ocean from Puerto Rico and **100%** ocean supply of Eliquis® from Italy to Australia on this lane in February.

Implemented reusable thermal shipping containers for market distribution in Canada, Puerto Rico and Mexico, reducing the amount of waste to landfill.

Our partner carrier for ocean freight service from Puerto Rico to the United States converted from barge service to liquefied natural gas (LNG) vessels, attributing an additional **14%** improvement in GHG emissions.

Implemented the use of a new shipping container from Italy to China and from the United States to Korea, providing a **400%** improvement in GHG emissions in these lanes.

Business

Goal 4 | Drive supply chain leadership on quality and integrity

Every year, our Global Procurement teams assess more than 900 suppliers who provide everything from the raw materials needed to develop and manufacture our medicines to the packaging they come in. Using our Product Risk Assessment and Mitigation (PRAM) process, we have determined which suppliers are critical to our brands and identified any potential risks that could affect our supply chain.

The Pharmaceutical Supply Chain Initiative (PSCI) is a group of pharmaceutical and healthcare companies who share a vision of better social, health, safety and environmental outcomes in the communities where we buy. PSCI believes that its members can share knowledge and expertise across our industry to drive complex, global change more effectively than any one organization alone.



Business

Goal 5 | Innovate to support a green, healthy planet

ENERGY

Our energy and water conservation efforts have led to significant reductions in our environmental footprint while also saving millions of dollars.

Hundreds of projects have been identified at 13 sites during Energy Treasure Hunts, which are led by our Global Energy Services department and engage broad numbers of employees to search out low-cost energy saving opportunities throughout their facilities.

Energy Star Partner of the Year (5 consecutive years)/Sustained Excellence (last 2 consecutive years)

Our Water Compass program to assess water and wastewater risk at 13 manufacturing sites is on track to complete by 4Q 2019. Understanding how we use this essential resource and treat wastewater is invaluable and supports our efforts to evaluate the impact of our business operations on our communities and the environment.

13 sites in 6 countries

200 participants

60 model practices observed | 150 opportunities

We are committed to
REDUCE 20%
energy intensity
within 10 years

Through the first
5 years, we have
achieved a
**REDUCTION OF
15.23%**



As Challenge Partners to the US Department of Energy's Better Plants Program, we made public commitments to reducing our energy intensity across our enterprise within 10 years. In addition, we commit to implementing plans that improve our environmental and economic independence through a focus on energy reduction.

Significant waste reduction efforts have been implemented across our enterprise. This work includes traditional efforts to reduce waste generated in all of our facilities to the impact on waste reduction from green chemistry and product packaging. We are the first biopharmaceutical company to join the Better Plants Waste Reduction Pilot program.

Sustainability at Bristol Myers Squibb means delivering on our mission to extend and enhance human life, including the way we design, construct and renovate our facilities.

In 2009, Bristol Myers Squibb established a Design Standard for new construction and major renovations based on elements taken from nationally recognized programs for energy efficiency and green building design.

Since 2009, Bristol Myers Squibb has received:

7 Silver LEED Certifications

4 Gold LEED Certifications

1 Silver or Gold Pending

2 Certified Sites Pending




Business

Goal 5 | Innovate to support a green, healthy planet

GREEN CHEMISTRY

Driven by the principles of green chemistry, we developed an approach to leverage measurement and prediction to improve process design.

Through this Greenness by Design strategy, we have introduced several domains of new technology, including continuous manufacturing and predictive data analytics, that have reduced the consumption of materials, energy and water, while also saving time and increasing safety.




ELECTRONIC SCORECARD THAT EVALUATES LABORATORY "GREEN" PRACTICES



FOUR CERTIFICATION LEVELS:

	2018*	2017
Aspiring	104	116
Certified	237	258
Gold	186	178
Platinum	129	116

* As of August 2018



Principles of Integrity

HOW WE DO BUSINESS

is as important to us as the patients we serve, the people who make it all possible and the communities where we live and work. Our mission and commitment, combined with our Principles of Integrity, serve as the foundation of our culture and how we do business.

The Principles reflect who we are and provide a common framework for how we interact with our colleagues, our patients, our partners and our global community. They are a part of every business decision we make.

PROTECTING OUR PATIENTS

We work together cooperatively with a unifying objective to keep patients at the center of everything we do. This mindset results in a standard approach to the way we develop, promote and manufacture our products.

PROTECTING OUR EMPLOYEES

We value and respect one another and share in our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

CONDUCTING OUR BUSINESS

We value Bristol Myers Squibb's good reputation. We act with honesty and integrity in all of our business interactions, inside and outside of our workplace, knowing that these interactions are essential to maintaining our reputation.

GOVERNING OUR ORGANIZATION

We cultivate an environment where our Principles of Integrity are embedded into what we do every day; where compliant and ethical behavior is recognized and valued.

APPLYING INTERNAL CONTROLS

We ensure accuracy, quality and appropriate handling and use of Bristol Myers Squibb information and other assets in everything we do. We act with integrity at all times.

MANAGING TRAVEL, MEETINGS AND EXPENSES

We are committed to the highest standards of ethical behavior related to business travel and expenses. We ensure accuracy in the reporting of all business expenses.





Sustainability

2020 GOALS PROGRESS UPDATE